Clinical Trials: Idiopathic Thrombocytopenic Purpura (ITP)

New York

New York; Mount Sinai Medical Center
RAISE (RAndomized placebo-controlled ITP Study with Eltrombopag)

A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP) [TRA102537]

International

Adelaide, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Frankston, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Gosford, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Malvern, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Melbourne, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Parkville, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Randwick, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Sydney, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Westmead, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Woolloongabba, Australia; Research Site:
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

Bari, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Bologna, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Brescia, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Cagliari, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Cuneo, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Milano, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Napoli, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Padova, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Palermo, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Pesaro, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Pescara, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Ravenna, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Reggio Emilia, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Roma, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Siena, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Taranto, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Udine, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Verona, Italy; Research Site:
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)